三個皮匠報告
政策庫
new
付費
搜索

AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比-行業數據

AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比
在全人群展現較好的療效風險比：全人群 ORR 明顯高于其他療法，同時大于等于三級以上 TRAE 發生率較低，未發現 ADC 可能導致的眼毒性風險。
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?05KB 圖片尺寸：2304*1446
同報告圖片
 / 28
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第1頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第2頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第3頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第4頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第5頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第6頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第7頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第8頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第9頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第10頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第11頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第12頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第13頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第14頁
fCDoja/niannu4TlkIggICAgICAgICAgICAgICB8IE9SUiAoJSkgfCBEQ1IgKCUpIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tfC0tLS0tLS0tLXwKfCBBSzExMiAoTj0zMjEpICAgICAgICB8IDU2LjMgICAgfCAxMDAuMCAgIHwKfCBQZW1icm9saXp1bWFiIChOPTI2MykgfCA0Mi4zICAgIHwgODQuNiAgICB8CnwgUGVtYnJvbGl6dW1hYiBpbiAoTj02MzcyKSB8IDI3LjMgICAgfCA2NS45ICAgIHwKCui1hOaWmeadpea6kO+8muaKlei1hOiAhea8lOekuuadkOaWme+8jOS4reazsOivgeWIuOeglOeptuaJgO+8jOaVsOaNruaIquiHszIwMjHlubTjgII=
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第15頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第16頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第17頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第18頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第19頁
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
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第20頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第21頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第22頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第23頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第24頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第25頁
fCDogqHkuJwgICAgICAgfCDmjIHogqHmr5TkvosgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5aSP55GcICAgICAgIHwgMTUuNyUgICAgfAp8IOWkj+awj+S/oeaJmCAgIHwgNi44NyUgICAgfAp8IOadjuawj+S/oeaJmCAgIHwgNS4wOCUgICAgfAp8IOeOi+awj+S/oeaJmCAgIHwgMS42MyUgICAgfAp8IOWFtuS7luiCoeS4nCAgIHwgNzAuNzIlICAgfAoK6LWE5paZ5p2l5rqQ77ya5ZCM6Iqx6aG677yM5Lit5rOw6K+B5Yi456CU56m25omA
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第26頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第27頁
fCDlj4LmlbAgfCBBSzEwNSB8IE5pdm9sdW1hYiB8IFBlbWJyb2xpenVtYWIgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgS0QgKE0pIHwgNS44OEUtMTAgfCA1LjQwRS0xMCB8IDcuMTdFLTEwIHwKfCBrb24gKDEvTXMpIHwgMS42MkUrMDUgfCA0LjUwRSswNSB8IDMuOTFFKzA1IHwKfCBrZGlzICgxL3MpIHwgOS41MUUtMDUgfCAyLjQzRS0wNCB8IDIuODBFLTA0IHwKfCBSbWF4IChSVSkgfCAzMi41Mi00Ni44MCB8IDMzLjk3LTQ4LjAxIHwgNDQuODQtNjMuOTEgfAoK6LWE5paZ5p2l5rqQ77ya44CKUGVtYnJvbGl6dW1hYiwgYW4gRmMtRW5naW5lZXJlZCBJZ0cxIEFudGktUEQtMSBBbnRpYm9keSwgV2l0aCBJbXByb3ZlZCBFZmZpY2FjeSBhbmQgTG93IEluY2lkZW5jZSBvZiBJbW11bmUtUmVsYXRlZCBBZHZlcnNl44CL
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第28頁
AK104治療末線宮頸癌對比其他國內外指南優先推薦療法在全人群展現較好的療效風險比_第29頁
fCDlk4HniYwgICAgICAgfCDljaDmr5QgIHwKfC0tLS0tLS0tLS0tLXwtLS0tLS18CnwgQkFJIFpFIEFOICB8IDM1JSAgfAp8IFRZVllUICAgICAgfCAyNSUgIHwKfCBBTCBSVUkgS0EgIHwgMTUlICB8CnwgS0VZVFJVREEgICB8IDEwJSAgfAp8IFRVTyBZSSAgICAgfCA1JSAgIHwKfCBIQU4gU0hJIFpIVUFORyB8IDMlICB8CnwgVEVDRU5UUklRICB8IDIlICAgfAp8IE9QRElWTyAgICAgfCAyJSAgIHwKfCBBTiBOSSBLRSAgIHwgMSUgICB8CnwgRU4gV0VJIERBICB8IDElICAgfAp8IE9USEVSUyAgICAgfCAxJSAgIHwKCui1hOaWmeadpea6kO+8mklRVklB77yM5Lit5rOw6K+B5Yi456CU56m25omA
所屬報告： 康方生物-港股公司研究報告-雙特異抗體龍頭國際化之路現勝利曙光-240621（37頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站